Tempus AI to Acquire Personalis for $1.5B; Both Stocks Sink on Dilution Fears
TEM is trading near its 52-week low of $41.73 (14% above the low).
Summary
Tempus AI is buying cancer testing firm Personalis in an all-stock deal valued at $1.5 billion, or $16.25 per share — a modest 5.6% premium to Friday's close. The market is voting no: Tempus shares fell 8.8% to $47.81, breaking below the 50-day moving average, while Personalis dropped 9.4% to $13.90, well below the offer price, signaling skepticism about deal execution or dilution. Tempus already holds a 12.5% stake and expects the deal to close by early 2027, integrating Personalis's MRD test into its AI diagnostics platform. This follows a strong Q1 with 36% revenue growth but widening losses, and a recent $460 million convertible note offering — the acquisition adds strategic depth but also execution risk. The negative reaction suggests investors are questioning the price tag and the all-stock structure's impact on existing shareholders.
At the time of this announcement, TEM was trading at $47.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.6B. The 52-week trading range was $41.73 to $104.32. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.